BioCryst Pharmaceuticals Interest Expense 2011-2026 | BCRX

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense BioCryst Pharmaceuticals

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008
-	-	108 M	99.1 M	59.3 M	14.5 M	11.9 M	9.18 M	8.56 M	6.49 M	5.2 M	5 M	4.78 M	4.67 M	3.77 M	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
108 M	3.77 M	26.2 M

Quarterly Interest Expense BioCryst Pharmaceuticals

2026-Q1	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-1.46 M	-	-	-	-	-	24.7 M	24.5 M	-	27.3 M	28.9 M	27.4 M	-	24.8 M	24 M	23.8 M	-	14.1 M	13.5 M	12.9 M	-	2.93 M	2.92 M	3.05 M	-	3.04 M	3.04 M	2.73 M	-	2.35 M	2.2 M	2.22 M	-	2.14 M	2.09 M	2.1 M	-	1.46 M	1.42 M	1.47 M	-	1.24 M	1.31 M	1.32 M	-	1.22 M	1.22 M	1.24 M	-	1.19 M	1.16 M	1.18 M	-	1.17 M	1.16 M	1.16 M	-	1.16 M	1.17 M	288 K

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
28.9 M	-1.46 M	7.07 M

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
FSD Pharma HUGE	9.34 K	-	5743.5 %	$ 69.7 M	Canada
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Happiness Biotech Group Limited HAPP	262 K	-	1.35 %	$ 17.8 M	China
AgeX Therapeutics AGE	51 K	-	-10.17 %	$ 12.2 K	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
Deciphera Pharmaceuticals DCPH	16.4 M	-	-	$ 2.18 B	USA
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
Compugen Ltd. CGEN	281 K	$ 2.17	-2.48 %	$ 203 M	Israel
BioNTech SE BNTX	14.2 M	$ 88.82	-0.86 %	$ 21.5 B	Germany
Coherus BioSciences CHRS	9 M	$ 1.52	-3.81 %	$ 178 M	USA
Athira Pharma ATHA	1.24 M	-	-	$ 269 M	USA
CRISPR Therapeutics AG CRSP	86.6 M	$ 53.21	-6.57 %	$ 4.78 B	Schweiz
Galera Therapeutics GRTX	11.4 M	-	-32.59 %	$ 7.61 M	USA
Berkeley Lights BLI	910 K	-	-7.31 %	$ 87 M	USA
Celldex Therapeutics CLDX	927 K	$ 29.81	-0.42 %	$ 1.98 B	USA
IMV IMV	2.34 K	-	-	$ 13.1 M	Canada
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
Enlivex Therapeutics Ltd. ENLV	1.93 M	$ 0.75	-4.78 %	$ 34.3 M	Israel
Esperion Therapeutics ESPR	3.49 M	$ 3.13	-	$ 651 M	USA
Eton Pharmaceuticals ETON	1.06 M	$ 28.73	-0.59 %	$ 773 M	USA
Cyclacel Pharmaceuticals CYCCP	354 K	-	-4.36 %	$ 27 M	USA
Freeline Therapeutics Holdings plc FRLN	2.15 M	-	-	$ 384 M	Britain
Gracell Biotechnologies GRCL	6.74 M	-	-	$ 3.37 B	China
Forte Biosciences FBRX	-396 K	$ 16.17	-3.15 %	$ 209 M	USA
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Can-Fite BioPharma Ltd. CANF	561 K	$ 3.16	0.01 %	$ 5.2 M	Israel
Aptinyx APTX	737 K	-	-39.0 %	$ 4.57 M	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
AlloVir ALVR	1.44 M	-	4.14 %	$ 49.1 M	USA